Stockholm – 16 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included in the “Novel strategies in multiple myeloma” session and was led by Professor ... read more

Stockholm – 14 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1... read more

Stockholm – 13 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will make a review and update on the presented data from the European Hematology Meeting (EHA) on Monday, June 17, 2019, at. 09:00 (CET). It will be presented by CEO Jakob Lindberg an... read more

DUBLIN, Ireland and TREVOSE, Pa., June 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announc... read more

GAITHERSBURG, Md., June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has... read more